Company Overview of CuraGen Corporation
CuraGen Corporation develops novel therapeutics for the treatment of cancer in the United States and Europe. The company focuses on the development of CR011-vcMMAE, a Phase II clinical trail drug for the treatment of patients with metastatic melanoma and breast cancer. It has strategic collaborations with Amgen Fremont to develop fully-human monoclonal antibody therapeutics; and Seattle Genetics, Inc. to license Seattle Genetics’ proprietary antibody- drug conjugate technology. The company was incorporated in 1991 and is headquartered in Branford, Connecticut. As of October 1, 2009, CuraGen Corporation operates as a subsidiary of Celldex Therapeutics, Inc.
322 East Main Street
Branford, CT 06405
Founded in 1991
Key Executives for CuraGen Corporation
Similar Private Companies By Industry
|Crescendo Pharmaceuticals Corporation||United States|
|Protein Pathways, Inc.||United States|
|Cambrian Genomics Inc.||United States|
|Newport Laboratories, Inc.||United States|
|Xenerex Biosciences, Inc.||United States|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
To contact CuraGen Corporation, please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.